Neutralization titers against omicron up with mRNA-1273 boost
Jan 28, 2022
After a mRNA-1273 (Moderna) boost, neutralization titers against the omicron variant were 20 times higher than than those at one month after second dose.
Thrombosis, thrombocytopenia syndrome up after Ad26.COV2.S
Jan 28, 2022
Rates of 3.83 per million vaccine doses for Ad26.COV2.S (Johnson & Johnson) have been reported, versus 0.00855 per million for mRNA-based vaccines such as Pfizer-BioNTech and Moderna.
Supreme Court hears arguments on Biden’s vaccine mandate for big business
Jan 07, 2022
The court also was hearing arguments on separate vaccine mandate for most heathcare workers.
Vaccination seems less protective against transmission of delta variant
Jan 07, 2022
The reduction in transmission of SARS-CoV-2 associated with COVID-19 vaccination was smaller for the delta variant versus the alpha variant.
NVX-CoV2373 vaccine protects against COVID-19
Dec 27, 2021
A study conducted in the U.S. and Mexico shows that the vaccine is 90% effective overall and 100% effective against moderate-to-severe disease.
mRNA COVID-19 vaccine less protective in elderly with comorbidity
Dec 23, 2021
At ≥7 days after the second dose, the effectiveness of mRNA COVID-19 vaccine was 69% against infection and 86% against related death.
No increase seen in CV events in elderly after BNT162b2 vaccination
Dec 10, 2021
No increase was seen in the incidence of myocardial infarction, stroke or pulmonary embolism among those aged 75 years or older in France.
Rates of COVID-19, severe illness lower with BNT162b2 booster dose
Dec 09, 2021
A second study shows a reduction in the rate of death due to COVID-19 with a booster dose of BNT162b2 (Pfizer–BioNTech).
Odds of SARS-CoV-2 infection down after third BNT162b2 dose
Dec 03, 2021
The estimated odds ratio of 0.14 at 28 to 65 days after receipt of the Pfizer-BioNTech booster was compared with those who received two doses.
Statin use not linked to COVID-19 mortality in hospitalized patients
Nov 09, 2021
Statin use was associated with an increased relative risk for severe disease among hospitalized patients with COVID-19.